46 completed, 21 recruiting, 12 active not recruiting, 8 terminated. 98 Phase 3, 14 Phase 2.
Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis Rozanolixizumab - Ocular Myasthenia Gravis | Phase 3 | Recruiting | UCB Biopharma SRL | 100 | 2026-09-16 | 2026-11-06 |
| Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) Ravulizumab - Generalized Myasthenia Gravis, gMG | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2026-07-27 | 2026-10-21 |
| A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) Claseprubart, Placebo - Myasthenia Gravis, Generalized | Phase 3 | Recruiting | Dianthus Therapeutics | 195 | 2026-06-29 | 2026-10-30 |
| A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis Rozanolixizumab, Placebo - Ocular Myasthenia Gravis | Phase 3 | Recruiting | UCB Biopharma SRL | 120 | 2026-05-27 | 2026-11-06 |
| Zilucoplan for Severe gMG Exacerbations Zilucoplan® - Generalized Myasthenia Gravis (gMG) | Phase 3 | Recruiting | Miriam Freimer | 15 | 2026-01-20 | 2026-08-28 |
| A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) Telitacicept, Placebo - Myasthenia Gravis, Ocular | Phase 3 | Recruiting | RemeGen Co., Ltd. | 120 | 2026-01-13 | 2026-04-09 |
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis Nipocalimab, Efgartigimod - Myasthenia Gravis | Phase 3 | Recruiting | Janssen Research & Development, LLC | 115 | 2026-01-05 | 2026-11-03 |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX - Optic Neuritis, Myelitis | Phase 3 | Recruiting | Mayo Clinic | 382 | 2025-07-11 | 2026-09-24 |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis IMVT-1402, Placebo - Generalized Myasthenia Gravis | Phase 3 | Recruiting | Immunovant Sciences GmbH | 231 | 2025-05-27 | 2026-11-13 |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis Decartes-08, Placebo Drug - Myasthaenia Gravis | Phase 3 | Active not recruiting | Cartesian Therapeutics | 128 | 2025-05-06 | 2026-09-01 |
| Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. immediate treatment with corticosteroids, addition of rituximab if recurrence - Ocular Myasthenia Gravis | Phase 3 | Recruiting | Fondation Ophtalmologique Adolphe de Rothschild | 128 | 2025-04-29 | 2026-01-21 |
| Blinatumomab for Treatment of Refractory Myasthenia Gravis Blinatumomab - Myasthenia Gravis | Phase 2 / Phase 3 | Not yet recruiting | Da, Yuwei, M.D. | 2 | 2025-04-01 | 2025-03-25 |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label) - Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 180 | 2025-02-07 | 2026-09-28 |
| Efgartigimod in IVIG Dependent Myasthenia Gravis Patients efgartigimod administration - Myasthaenia Gravis | Phase 3 | Recruiting | Clinique Neuro-Outaouais | 30 | 2025-02-06 | 2026-10-22 |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG Eculizumab - Generalized Myasthenia Gravis (gMG), Refractory gMG | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 15 | 2025-01-06 | 2026-01-15 |
| An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Zilucoplan - Generalized Myasthenia Gravis | Phase 3 | Enrolling by invitation | UCB Biopharma SRL | 8 | 2024-11-19 | 2026-10-02 |
| PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis Gefurulimab - Generalized Myasthenia Gravis, gMG | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2024-11-13 | 2026-04-01 |
| Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy - Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Phase 3 | Recruiting | The First People's Hospital of Changzhou | 200 | 2024-11-08 | 2026-06-09 |
| A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Zilucoplan - Generalized Myasthenia Gravis | Phase 2 / Phase 3 | Recruiting | UCB Biopharma SRL | 8 | 2024-10-16 | 2026-11-05 |
| An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis rozanolixizumab - Generalized Myasthenia Gravis | Phase 3 | Active not recruiting | UCB Biopharma SRL | 13 | 2024-10-08 | 2026-11-06 |
Showing 20 of 98. Sign in to see all of them.
Myasthenia Gravis (79) · Myelitis, Transverse (8) · Neuromyelitis Optica (6) · ACTH Syndrome, Ectopic (5) · Cushing Syndrome (5) · Optic Neuritis (5) · Demyelinating Diseases (4) · Pituitary ACTH Hypersecretion (4) · Recurrence (4) · Autoimmune Diseases (3) · Pituitary Diseases (3) · Adrenal Cortex Neoplasms (2) · Choristoma (2) · Diabetes Mellitus, Type 2 (2) · Hirsutism (2)
Neoplasms (98) · Nervous System Diseases (95) · Neoplasms by Site (93) · Nervous System Neoplasms (91) · Neurodegenerative Diseases (91) · Paraneoplastic Syndromes, Nervous System (91) · Immune System Diseases (90) · Autoimmune Diseases of the Nervous System (89) · Autoimmune Diseases (87) · Neuromuscular Diseases (81) · Neuromuscular Junction Diseases (81) · Central Nervous System Diseases (14) · Neuroinflammatory Diseases (9) · Pathological Conditions, Signs and Symptoms (9)
rozanolixizumab (8) · eculizumab (7) · zilucoplan (7) · Amifampridine (5) · efgartigimod alfa (5) · Rituximab (4) · ravulizumab (4) · Corlux (3) · Mifepristone (3) · Tacrolimus (3) · telitacicept (3) · Adrenal Cortex Hormones (2) · Cyclophosphamide (2) · HBM9161 (2) · Immunoglobulins, Intravenous (2)
Alexion Pharmaceuticals, Inc. (13) · UCB Biopharma SRL (13) · argenx (10) · Corcept Therapeutics (5) · Catalyst Pharmaceuticals, Inc. (4) · Astellas Pharma Inc (3) · Janssen Research & Development, LLC (3) · AstraZeneca (2) · First Affiliated Hospital, Sun Yat-Sen University (2) · Harbour BioMed (Guangzhou) Co. Ltd. (2) · Hoffmann-La Roche (2) · Immunovant Sciences GmbH (2) · Novartis Pharmaceuticals (2) · RemeGen Co., Ltd. (2) · University Health Network, Toronto (2)
United States (64) · Italy (46) · Poland (44) · Spain (43) · Japan (42) · Canada (41) · Germany (40) · France (32) · United Kingdom (32) · China (26) · Denmark (22) · Georgia (21) · Netherlands (20) · Belgium (19) · South Korea (19)
Andreas Moraitis, MD (2) · Gil Wolfe, MD (2) · Renato Mantegazza, MD (2) · Vera Bril, MD (2) · Antonio Guglietta, MD (1) · Brian G. Weinshenker (1) · Charles W Gorodetzky, MD, PhD (1) · Chongbo Zhao (1)
PMID 37059507, PMID 42388397, PMID 25013998, PMID 26507877, PMID 30905021, PMID 32189108, PMID 32426038, PMID 32700461, PMID 33229455, PMID 33329303, PMID 33676197, PMID 34146511, PMID 34498507, PMID 34590717, PMID 37059508, PMID 38400914, PMID 39314260, PMID 40105996, PMID 40504283, PMID 42855714, PMID 18567886, PMID 18675464, PMID 21784757, PMID 22047648, PMID 22466348, PMID 23278584, PMID 23970725, PMID 25032816, PMID 26009577, PMID 27509100, PMID 28639937, PMID 28861121, PMID 29066163, PMID 30692052, PMID 30767274, PMID 31050279, PMID 31115842, PMID 31698177, PMID 32611638, PMID 33219142, PMID 33310418, PMID 33796147, PMID 34795626, PMID 34803867, PMID 35058882, PMID 36121672, PMID 36852670, PMID 36890354, PMID 37103755, PMID 38099334
2023 (8), 2019 (4), 2018 (3), 2025 (3), 2014 (1), 2016 (1), 2017 (1), U01NS042685 (1)